opc 21268 has been researched along with vesnarinone in 1 studies
| Studies (opc 21268) | Trials (opc 21268) | Recent Studies (post-2010) (opc 21268) | Studies (vesnarinone) | Trials (vesnarinone) | Recent Studies (post-2010) (vesnarinone) |
|---|---|---|---|---|---|
| 133 | 3 | 6 | 215 | 17 | 8 |
| Protein | Taxonomy | opc 21268 (IC50) | vesnarinone (IC50) |
|---|---|---|---|
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.0965 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | 6.2 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | 6.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashida, W; Kawai, C; Kumada, T | 1 |
1 review(s) available for opc 21268 and vesnarinone
| Article | Year |
|---|---|
[New oral drugs for the treatment of congestive heart failure].
Topics: Administration, Oral; Cardiotonic Agents; Deoxyepinephrine; Ethanolamines; Heart Failure; Humans; Phosphodiesterase Inhibitors; Piperidines; Propanolamines; Pyrazines; Quinolines; Quinolones; Vasodilator Agents; Xamoterol | 1992 |